Utilization of archived neonatal dried blood spots for genome-wide genotyping

Pagna Sok, Philip J. Lupo, Melissa A. Richard, Karen R. Rabin, Erik A. Ehli, Noah A. Kallsen, Gareth E. Davies, Michael E. Scheurer, Austin L. Brown

1 Department of Pediatrics, Hematology-Oncology Section, Baylor College of Medicine, Houston, Texas, United States of America, 2 Avera Institute for Human Genetics, Sioux Falls, South Dakota, United States of America

* Austin.Brown@bcm.edu

Abstract

Introduction
Heel pricks are performed on newborns for diagnostic screenings of various pre-symptomatic metabolic and genetic diseases. Excess blood is spotted on Guthrie cards and archived by many states in biobanks for follow-up diagnoses and public health research. However, storage environment may vary across biobanks and across time within biobanks. With increased applications of DNA extracted from spots for genetic studies, identifying factors associated with genotyping success is critical to maximize DNA quality for future studies.

Method
We evaluated 399 blood spots, which were part of a genome-wide association study of childhood leukemia risk in children with Down syndrome, archived at the Michigan Neonatal Biobank between 1992 and 2008. High quality DNA was defined as having post-quality control call rate \( \geq 99.0\% \) based on the Illumina GenomeStudio 2.0 GenCall algorithm after processing the samples on the Illumina Infinium Global Screening Array. Bivariate analyses and multivariable logistic regression models were applied to evaluate effects of storage environment and storage duration on DNA genotyping quality.

Results
Both storage environment and duration were associated with sample genotyping call rates (p-values < 0.001). Sample call rates were associated with storage duration independent of storage environment (p-trend = 0.006 for DBS archived in an uncontrolled environment and p-trend = 0.002 in a controlled environment). However, 95% of the total sample had high genotyping quality with a call rate \( \geq 95.0\% \), a standard threshold for acceptable sample quality in many genetic studies.

Conclusion
Blood spot DNA quality was lower in samples archived in uncontrolled storage environments and for samples archived for longer durations. Still, regardless of storage environment or
duration, neonatal biobanks including the Michigan Neonatal Biobanks can provide access to large collections of spots with DNA quality acceptable for most genotyping studies.

Introduction

Blood obtained from heel pricks of newborn infants are spotted on Guthrie cards and collected as part of newborn screening (NBS) programs to identify potentially life-threatening metabolic and genetic disorders including sickle cell disease, phenylketonuria, and numerous other conditions associated with long-term morbidity [1–7]. Many states store excess or residual dried blood spots (DBS) that are not needed for the NBS in long-term repositories. In states that permit the use of these DBS for biomedical research, DBS can then be linked to disease registries, providing a rich resource for population-based epidemiologic studies for conditions not typically evaluated as part of NBS programs [8, 9]. Thus far, conditions studied have included type 1 diabetes, multiple sclerosis, and childhood cancers among many others [10–12]. While DBS are increasingly being utilized to conduct genome-wide association studies for a range of phenotypes [13, 14], DBS may be in archive for decades under various conditions, which may affect the quality of DNA quality retrieved for research purposes [15–17]. The Michigan Neonatal Biobank (MNB) is a storage and management center for archiving DBS collected as part of the Michigan NBS program. The MNB has archived over five million DBS to date, which represents almost every live birth in the state since 1987. We examined the effects of multiple factors, including storage environment and storage duration, on the quality of DNA extracted from DBS retrieved from the MNB for genome-wide genotyping. Our overall goal was to understand the potential compromising factors to be considered when identifying DBS while still maximizing samples to utilize for genetic epidemiologic studies. Particularly, for genomic analyses of rare childhood conditions, utilizing archived DBS that are several decades old may be necessary to amassed an adequate sample size to achieve statistical power for rare variants evaluation.

Methods

Neonatal DBS were obtained from MNB as part of a genome-wide association study of childhood leukemia risk in children with Down syndrome [18], which permits all original 425 genotyped samples from children born between 1992 and 2008 to be evaluated. Birth records at the Michigan Department of Health and Human Services were linked to the records in the Michigan Cancer Surveillance Program to identify individuals with Down syndrome with and without acute lymphoblastic leukemia in the Michigan Cancer Surveillance program. This study was approved by the Committee for the Protection of Human Subjects of the Health and Human Services Agency of the State of Michigan and the Institutional Review Board of Baylor College of Medicine and did not involve the use of any personal identifiers.

DNA extraction

DNA extraction and genotyping for all DBS samples were conducted in 2017. DNA extraction was performed using the GenTegra (Pleasanton, CA) GenSolve Whole Blood DNA recovery kit according to the manufacturer protocol, which allows for DNA recovery from Whatman FTA (Flinders Technology Associates) cards, regardless of storage time. For each unique sample, six 3-mm punches were combined into a single 1.5 mL microtube containing the specified amount of GenTegra Recovery Solution A/Proteinase K solution. Following incubation in a
heated shaker for a minimum of 1 hour, the tubes were centrifuged to collect any condensation. Remnant punches were removed before the solution was mixed with GenTegra Recovery Solution B. The entire volume was then transferred to either the NucleoSpin XS (Macherey-Nagel Inc., Bethlehem, PA) or Qiagen Micro (Hilden, Germany) spin column for DNA purification according to manufacturer recommendations. Total DNA was then eluted from each respective spin column by addition of approximately 35 μL of AE buffer. Quantification of the purity of the extracted DNA was performed using the Thermo Fisher Scientific NanoDrop 2000 Spectrophotometer (Wilmington, DE).

**DNA genotyping and quality control**

Extracted DNA was genotyped at the Avera Institute for Human Genetics (Sioux Falls, SD) using the Illumina (San Diego, CA) Infinium Global Screening Array BeadChip, which captures approximately 700,000 single nucleotide polymorphisms (SNPs). These genotyped SNPs or variants were called with GenomeStudio 2.0 software (San Diego, CA). The analysis was restricted to variants on chromosomes 1 to 20 and 22. Variants on chromosome 21 (n = 9,443) were excluded because calling for trisomic variants is not currently supported in GenomeStudio 2.0. We implemented conservative quality control criteria based on the GenomeStudio clustering algorithm metrics [19] rather than criteria often used in genome-wide association studies [20, 21], to filter poor-performing probes and specifically evaluate sample call rate from DBS. In particular, variants with a call rate < 90% (n = 17,804), minor allele frequency < 1% (n = 150,292), and cluster separation < 0.3 (n = 20,468) were removed. Final call rates were calculated among the 472,019 variants that passed quality control.

**DBS call rate as primary outcome**

GenomeStudio assigned variants genotyping based on a GenCall score generated through a calling algorithm. GenCall score is a quality metric between 0 and 1 that describes sample clustering, where a low score is assigned to samples that locate away from a cluster center. A low GenCall score is an indication of unreliable genotype calls, and typically, variants with a score < 0.15 are not assigned a genotype. Hence, sample call rate is the proportion of genotyped or called variants for an individual sample that were successfully determined by the GenomeStudio calling algorithm after initial removal of variants that did not pass quality control. Sample call rate was used as the primary outcome to evaluate DBS quality. Call rates were dichotomized on a stringent threshold such that a sample call rate ≥ 99.0% was classified as evidence of higher DNA quality while < 99.0% sample call rate indicated poorer DNA quality.

**DBS storage characteristics as primary exposure**

At MNB, DBS collected between 1996 and 2008 are kept in a controlled environment at 70 degrees Fahrenheit and 35% humidity while older DBS collected prior to 1996 are stored in an uncontrolled temperature and controlled (35%) humidity environment. Thus, the primary independent variables evaluated as potential factors differentiating DNA quality were storage environment and storage duration.

**Statistical methods**

Descriptive statistics, including counts and percentages for categorical variables and median and ranges for continuous variables, were calculated for the overall sample and compared across samples with call rate ≥ 99.0% or < 99.0%. Differences between sample quality and independent variables, including storage environment, storage duration, leukemia status,
infant sex, maternal race/ethnicity, total DNA yield, and 260/280 measurement (indicative of DNA quality) were evaluated using Pearson chi-square, Fisher’s exact, or Wilcoxon rank-sum test. Since storage environment was correlated with year of sample collection, we fitted multivariable logistic regression models to evaluate the association between period of sample collection and sample quality, stratified by storage environment: 1) collected prior to 1996 (n = 101) and 2) collected on or after 1996 (n = 298). Logistic regression models were adjusted for total DNA yield and maternal race/ethnicity. All statistical analyses were conducted in R 3.5.2 and a significance threshold p-value < 0.05 was applied. Finally, to identify if any chromosomal regions were more susceptible to DNA degradation due to differences in storage conditions, we applied Fisher’s exact test to evaluate missing call counts across post-quality control genotyped SNPs in PLINK 1.9 using storage environments as the dependent variable [22, 23]. Variants with 0% or 100% missing call frequency were not evaluated.

Results

DBS call rate quality

To compare sample quality of the 425 DBS collected from newborns born between 1992 and 2008, 26 samples were excluded due to differences in DNA extraction methods. Among the 399 remaining samples, 75% were collected between 1996 and 2008 and stored in a controlled environment at 70 degrees Fahrenheit and 35% humidity (Table 1). The proportion of DBS collected and archived each year constituted between 4–8% of the total for the 16-year time period, with the exception of 2% in the year 2004. The majority of the samples were collected from individuals without a known diagnosis of childhood leukemia (94%), male sex (52%), and non-Hispanic white maternal race/ethnicity (77%).

The median sample call rate was 98.8% (range = 79.9–99.0%) prior to variant filtering. Variant filtering statistically improved call rate (median = 99.9%, range = 80.4–99.9%, p-value < 0.001) where 339 (85%) DBS had a call rate ≥ 99.0% after filtering (Table 1). The number of samples with call rate < 99.0% occurred more frequently in those collected prior to 1996 that were stored in a laboratory retention center without a controlled environment (p-value < 0.001). In contrast, the proportion of samples with call rate ≥ 99.0% archived on or after 1996 exceeded 85% every year, with the exception of 1997 (79%) and 1998 (79%). Maternal race/ethnicity was significantly associated with call rate (p-value = 0.04); however, this association was no longer statistically significant in models accounting for year of birth, suggesting that differences in call rates between racial/ethnic groups was confounded by changes in demographic dynamics of the population during the DBS collection period.

DBS call rate quality by storage environment and duration

We observed improvements in median sample call rate by year of DBS collection and archive environment (Fig 1). This trend was apparent both prior to and following variant filtering. To evaluate if the association between sample call rates and date of sample collection remained after accounting for differences in storage conditions, we conducted multivariable logistic regression stratifying on storage environment (Table 2). Independent of storage environment, there was also a positive correlation between the proportion of DBS with call rate ≥ 99.0% and more recent collection years. This was true for both DBS collected prior to 1996 (p-value for trend = 0.006) and samples collected on or after 1996 (p-value for trend = 0.002). We did not identify statistically significant associations between storage environments (S1 Table) and leukemia status (p-value = 0.9), infant sex (p-value = 0.9), maternal race/ethnicity (p-value = 0.9), or total DNA extracted (p-value = 0.05). Although DBS placement along the genotyping array was randomized, we further evaluated DBS placement as a potentially factor affecting call rate.
and did not observed any significant associations with call rate, storage environment, or DBS collection year (S2 Table). Moreover, DBS placement was not statistically associated with call rate (p-value = 0.5, data not shown) in the multivariable models accounting for total DNA yield, DBS collection year, maternal race/ethnicity, and storage environment. Therefore, DBS placement was not included in the final models presented.

Finally, we evaluated SNP missing frequency by storage environment and found random missing frequency across all chromosomes (Table 3, S1 Fig). Genome-wide statistically significant (p-value < 5×10^{-8}) differential missingness was observed between storage environments

Table 1. Associations between residual DBS characteristics and call rate among DBS archived at the Michigan Neonatal Biobank between 1992 and 2008.

| Residual DBS characteristics | Overall (n = 399) | Sample Call Rate | p-val<sup>1</sup> | \( \geq 99.0\% \) (n = 339) | < 99.0\% (n = 60) |
|-----------------------------|------------------|------------------|-------------------|----------------------|------------------|
| **Storage environments, n (%)** |                  |                  |                   |                      |                  |
| Uncontrolled environment<sup>2</sup> | 101 (25%)        | 54 (16%)         | 47 (78%)          | <0.001               |
| Controlled environment<sup>3</sup>  | 298 (75%)        | 285 (84%)        | 13 (22%)          |                      |
| **Year DBS collected, n (%)**     |                  |                  |                   |                      |                  |
| 1992                          | 26 (7%)          | 11 (3%)          | 15 (25%)          | <0.001               |
| 1993                          | 24 (6%)          | 8 (2%)           | 16 (27%)          |                      |
| 1994                          | 29 (7%)          | 17 (5%)          | 12 (20%)          |                      |
| 1995                          | 22 (6%)          | 18 (5%)          | 4 (7%)            |                      |
| 1996                          | 26 (7%)          | 26 (8%)          | 0 (0%)            |                      |
| 1997                          | 24 (6%)          | 19 (6%)          | 5 (8%)            |                      |
| 1998                          | 24 (6%)          | 19 (6%)          | 5 (8%)            |                      |
| 1999                          | 32 (8%)          | 31 (9%)          | 1 (2%)            |                      |
| 2000                          | 16 (4%)          | 16 (5%)          | 0 (0%)            |                      |
| 2001                          | 25 (6%)          | 25 (7%)          | 0 (0%)            |                      |
| 2002                          | 28 (7%)          | 28 (8%)          | 0 (0%)            |                      |
| 2003                          | 17 (4%)          | 15 (4%)          | 2 (3%)            |                      |
| 2004                          | 8 (2%)           | 8 (2%)           | 0 (0%)            |                      |
| 2005                          | 24 (6%)          | 24 (7%)          | 0 (0%)            |                      |
| 2006                          | 33 (8%)          | 33 (10%)         | 0 (0%)            |                      |
| 2007                          | 14 (4%)          | 14 (4%)          | 0 (0%)            |                      |
| 2008                          | 27 (7%)          | 27 (8%)          | 0 (0%)            |                      |
| **Leukemia status, n (%)**      |                  |                  |                   |                      |                  |
| Leukemia                     | 23 (6%)          | 21 (6%)          | 2 (3%)            | 0.6                  |
| No leukemia                  | 376 (94%)        | 318 (94%)        | 58 (97%)          |                      |
| **Infant sex, n (%)**         |                  |                  |                   |                      | 0.6               |
| Male                         | 206 (52%)        | 173 (51%)        | 33 (55%)          |                      |
| Female                       | 193 (48%)        | 166 (49%)        | 27 (45%)          |                      |
| **Maternal race/ethnicity, n (%)** |        |                  |                   |                      | 0.04              |
| Non-Hispanic White           | 308 (77%)        | 264 (78%)        | 44 (73%)          |                      |
| Non-Hispanic Black           | 57 (14%)         | 44 (13%)         | 13 (22%)          |                      |
| Non-Hispanic Asian           | 13 (3%)          | 10 (3%)          | 3 (5%)            |                      |
| Hispanic                     | 21 (5%)          | 21 (6%)          | 0 (0%)            |                      |
| **Total DNA yield in \( \mu g \), median (range)** | 5.3 (2.3–14.4) | 5.3 (2.4–14.4) | 4.8 (2.3–13.3) | 0.3 |

<sup>1</sup>Pearson chi-square, Fisher’s exact, or Wilcoxon rank-sum p-value comparing residual DBS characteristics by sample call rate.

<sup>2</sup>Uncontrolled temperature, 35% humidity.

<sup>3</sup>70 degrees Fahrenheit, 35% humidity.

https://doi.org/10.1371/journal.pone.0229352.t001
for 2.17% of all variants evaluated. The frequency of differential missingness was similar across each chromosome (range: 1.33–2.77%), suggesting storage condition adversely impaired DNA quality for genotyping indiscriminately.

**Discussion**

Utilizing archived residual DBS for genome-wide association research has increased in recent years [24, 25]. DBS have become a rich resource for population-based epidemiologic research...
on genetic factors of numerous diseases because of the accumulation of stored DBS along with the possibility to link samples to demographic and clinical data. However, due to the variability in the condition and environment that DBS are collected and archived within and between biobanks, it is good practice to consider the storage conditions and duration to evaluate the quality of extracted DNA across samples being used for any genomic studies. We evaluated sample call rate, a measurement of genotyping quality, of DBS archived at the MNB under varying storage conditions since their collection at births between 1992 and 2008. While controlled storage environment and newer blood spots yielded higher call rates, overall, our findings suggest DBS from MNB are viable and a potentially valuable resource for genome-wide association studies of common genetic variants.

In our analysis, storage environment and duration were the only two factors associated with differences in call rate. Specifically, DBS archived in a temperature- and humidity-controlled environment yielded higher DNA call rates (median call rate = 99.9%) when compared to those stored in an uncontrolled environment (median call rate = 99.3%). This is consistent with previous reports suggesting DBS storage environment influences biomarker stability [26, 27]. However, it should be noted that the average call rate for samples stored in an uncontrolled environment was acceptable for most genotyping applications. In this study, we used a call rate threshold of ≥ 99.0% to identify “high-quality” genotypes. Based on this, 85% of the selected samples were considered high quality (96% for those archived in a controlled environment). Moreover, many genome-wide association studies apply a less stringent call rate threshold of ≥ 95.0% to identify samples of acceptable quality [20, 21]. Using that threshold, 95.5% of the total DBS had sample call rates exceeding 95.0%, including 83% of the samples stored in an uncontrolled environment. Therefore, the majority of DBS regardless of their archival condition and duration should pass conventional quality control filtering applied in most

Table 2. Trend in proportions of call rate by collection years among DBS archived at the Michigan Neonatal Biobank between 1992 and 2008.

| Storage environments | Year DBS collected | Total DBS collected | DBS proportion with call rate ≥ 99.0% | p-trend¹ |
|-----------------------|-------------------|---------------------|--------------------------------------|---------|
| Uncontrolled environment² | 1992 | 26 | 0.42 | 0.006 |
| | 1993 | 24 | 0.33 |
| | 1994 | 29 | 0.59 |
| | 1995 | 22 | 0.82 |
| Controlled environment³ | 1996 | 26 | 1.00 | 0.002 |
| | 1997 | 24 | 0.79 |
| | 1998 | 24 | 0.79 |
| | 1999 | 32 | 0.97 |
| | 2000 | 16 | 1.00 |
| | 2001 | 25 | 1.00 |
| | 2002 | 28 | 1.00 |
| | 2003 | 17 | 0.88 |
| | 2004 | 8 | 1.00 |
| | 2005 | 24 | 1.00 |
| | 2006 | 33 | 1.00 |
| | 2007 | 14 | 1.00 |
| | 2008 | 27 | 1.00 |

¹Multivariable logistic regression model adjusted for DNA yield and maternal race/ethnicity.
²Uncontrolled temperature, 35% humidity.
³70 degrees Fahrenheit, 35% humidity.

https://doi.org/10.1371/journal.pone.0229352.t002
contemporary genetic association studies. While proper archival of residual DBS in controlled environments will likely lessen DNA degradation over time, for the purposes of genotyping on array-based technology, DBS stored in an uncontrolled environment are still usable for most genetic studies. Additionally, our results suggest that DNA quality was consistent across the genome regardless of storage environments, indicating that little if any bias exists in evaluating certain genomic regions.

As noted, storage duration affected call rates regardless of DBS storage environment, where the most recently archived DBS yielded higher DNA call rates. This association was similarly described previously [28, 29], with the effect of storage duration on DNA quality reduced among DBS archived in a controlled environment. However, despite the significant association between storage duration and call rate, the vast majority of DBS archived in a controlled environment had a call rate \( \geq 99.0\% \) (the exceptions are collection year 1997, 1998, and 2003 where there were DBS with call rate \(<99.0\%\)). Conversely, among DBS archived in an uncontrolled environment, the proportion of DBS with call rate \( \geq 99.0\% \) seems to increase linearly by storage year (Table 2), suggesting an improved call rate in more recently collected DBS.

This study evaluated the impact of environmental condition, storage duration, and demographic factors on genotyping quality obtained from nearly 400 residual DBS archived over two decades. While this study provides important information on correlates of DBS sample quality for array-based genotyping, the study findings should be considered in light of some limitations. First, our analyses are limited to assessment of DNA used for genotyping studies. More specifically, it is not clear if the quality of DNA extracted from DBS is sufficient for the detection of variants using whole-exome or whole-genome sequencing technologies. Notably, we obtained relatively high DNA yields from DBS [30, 31]; however, total yield may not

Table 3. Proportions of differential missing SNPs by storage environment among DBS archived at the Michigan Neonatal Biobank between 1992 and 2008.

| Chromosome | Number of SNPs evaluated | Number of SNPs with \( p \)-value \( \leq 5\times10^{-8} \) | Proportion of SNPs with \( p \)-value \( \leq 5\times10^{-8} \) |
|------------|--------------------------|-----------------------------------------------|-----------------------------------------------|
| 1          | 26966                    | 521                                           | 0.019                                         |
| 2          | 28580                    | 630                                           | 0.022                                         |
| 3          | 24467                    | 552                                           | 0.023                                         |
| 4          | 23160                    | 641                                           | 0.028                                         |
| 5          | 21205                    | 512                                           | 0.024                                         |
| 6          | 26951                    | 628                                           | 0.023                                         |
| 7          | 20210                    | 495                                           | 0.024                                         |
| 8          | 18607                    | 461                                           | 0.025                                         |
| 9          | 15502                    | 328                                           | 0.021                                         |
| 10         | 17538                    | 355                                           | 0.020                                         |
| 11         | 17105                    | 331                                           | 0.019                                         |
| 12         | 16769                    | 352                                           | 0.021                                         |
| 13         | 12769                    | 353                                           | 0.028                                         |
| 14         | 11316                    | 252                                           | 0.022                                         |
| 15         | 10529                    | 188                                           | 0.018                                         |
| 16         | 11242                    | 164                                           | 0.015                                         |
| 17         | 10895                    | 187                                           | 0.017                                         |
| 18         | 10504                    | 247                                           | 0.024                                         |
| 19         | 7836                     | 121                                           | 0.015                                         |
| 20         | 8521                     | 120                                           | 0.014                                         |
| 22         | 5121                     | 68                                            | 0.013                                         |
| All chromosomes | 345793  | 7506                                           | 0.022                                         |

https://doi.org/10.1371/journal.pone.0229352.t003
accurately reflect DNA quality and DNA degradation remains a concern. For more accurate estimations of quality DNA yield, future studies using DBS may want to consider specifically measuring dsDNA, which was not done in the current study. Additionally, because of our limited sample size, we were not able to fully evaluate the quality of low frequency variants (i.e., <1%) that are sometimes included in genome-wide association studies. Finally, because the samples included in this study were collected from a single bloodspot biobank, our findings may not be generalizable to DBS obtained from other biobanks with incomparable DBS archival environments.

In summary, residual DBS are a unique resource that facilitate population-based epidemiologic investigations of inherited genetic variation, epigenetic profiles, metabolomics and other potential biomarkers of complex diseases [27, 32–34], especially for rare pediatric outcomes. The results of this study illustrate that residual DBS archived at MNB provide high quality DNA for genetic association studies evaluating common variation using standard array-based genotyping. While we identified differences in average sample quality across storage environment and storage duration, these factors did not substantially limit the number of samples that would pass conventional quality control measures for most genome-wide association studies. For investigations of common phenotypes or limited sample sizes, priority may be given to more recently collected DBS and those stored in controlled environments. However, our findings generally support the use of DBS stored for extended periods in uncontrolled environments for investigations of rare phenotypes, which may require accruing cases occurring over a period of several decades in order to achieve acceptable sample sizes.

Supporting information

S1 Table. Associations between residual DBS characteristics and storage environment among DBS archived at the Michigan Neonatal Biobank between 1992 and 2008. (DOCX)

S2 Table. Counts of residual DBS call rate, storage environment, and collection period by genotyping array position among DBS archived at the Michigan Neonatal Biobank between 1992 and 2008. (DOCX)

S1 Fig. Manhattan plot showing the association of SNPs with storage environment among DBS archived at the Michigan Neonatal Biobank between 1992 and 2008. Black and red horizontal lines signify p-value $\leq 1 \times 10^{-5}$ and $\leq 5 \times 10^{-8}$, respectively. (TIFF)

Acknowledgments

We want to thank the Michigan Department of Health and Human Services and the Michigan Neonatal Biobank for their input and feedback on the acquisition and use of residual newborn screening dried blood spot specimens.

Author Contributions

**Conceptualization:** Philip J. Lupo, Michael E. Scheurer, Austin L. Brown.

**Data curation:** Erik A. Ehli, Noah A. Kallsen, Gareth E. Davies, Austin L. Brown.

**Formal analysis:** Pagna Sok.

**Funding acquisition:** Philip J. Lupo, Karen R. Rabin, Austin L. Brown.
Investigation: Karen R. Rabin.

Methodology: Philip J. Lupo, Melissa A. Richard, Erik A. Ehli, Noah A. Kallsen, Gareth E. Davies, Austin L. Brown.

Supervision: Philip J. Lupo, Michael E. Scheurer.

Validation: Pagna Sok.

Visualization: Pagna Sok.

Writing – original draft: Pagna Sok.

Writing – review & editing: Pagna Sok, Philip J. Lupo, Melissa A. Richard, Karen R. Rabin, Erik A. Ehli, Noah A. Kallsen, Gareth E. Davies, Michael E. Scheurer, Austin L. Brown.

References

1. Guthrie R, Susi A. A Simple Phenylalanine Method for Detecting Phenylketonuria in Large Populations of Newborn Infants. Pediatrics. 1963 Sep; 32:338–43. PMID: 14063511

2. El-Hattab AW, Almannai M, Sutton VR. Newborn Screening: History, Current Status, and Future Directions. Pediatr Clin North Am. 2018 04; 65(2):389–405. https://doi.org/10.1016/j.pcl.2017.11.013 PMID: 29502920

3. Almannai M, Marom R, Sutton VR. Newborn screening: a review of history, recent advancements, and future perspectives in the era of next generation sequencing. Curr Opin Pediatr. 2016 12; 28(6):694–9. https://doi.org/10.1097/MOP.0000000000000414 PMID: 27552071

4. Pena LD, van Calcar SC, Hansen J, Edick MJ, Walsh Vockley C, Leslie N, et al. Outcomes and genotype-phenotype correlations in 52 individuals with VLCAD deficiency diagnosed by NBS and enrolled in the IBEM-IS database. Mol Genet Metab. 2016 08; 118(4):272–81. https://doi.org/10.1016/j.ymgme.2016.05.007 PMID: 27209629

5. Castellani C, Massie J, Sontag M, Southern KW. Newborn screening for cystic fibrosis. Lancet Respir Med. 2016 08; 4(8):653–61. https://doi.org/10.1016/S2213-2600(16)00053-9 PMID: 27053341

6. Chaturvedi S, DeBaun MR. Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: The last 40 years. Am J Hematol. 2016 Jan; 91(1):5–14. https://doi.org/10.1002/ajh.24235 PMID: 26547630

7. Millington DS, Kodo N, Norwood DL, Roe CR. Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. J Inherit Metab Dis. 1990; 13(3):321–4. https://doi.org/10.1007/BF01799385 PMID: 2122093

8. Choi EH, Lee SK, Ihm C, Sohn YH. Rapid DNA extraction from dried blood spots on filter paper: potential applications in biobanking. Osong Public Health Res Perspect. 2014 Dec; 5(6):351–7. https://doi.org/10.1016/j.ophrp.2014.09.005 PMID: 25562044

9. Lewis MH, Scheurer ME, Green RC, McGuire AL. Research results: preserving newborn blood samples. Sci Transl Med. 2012 Nov 7; 4(159):159cm12. https://doi.org/10.1126/scitranslmed.3004474 PMID: 23136040

10. Kyvsgaard JN, Overgaard AJ, Jacobsen LD, Thorsen SU, Pipper CB, Hansen TH, et al. Low perinatal zinc status is not associated with the risk of type 1 diabetes in children. Pediatr Diabetes. 2017 Nov; 18 (7):637–42. https://doi.org/10.1111/pedi.12476 PMID: 27873432

11. Nielsen NM, Munger KL, Koch-Henriksen N, Hougaard DM, Magyari M, Jørgensen KT, et al. Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study. Neurology. 2017 Jan 3; 88(1):44–51. https://doi.org/10.1212/WNL.0000000000003454 PMID: 27903815

12. Bhatti P, Doody DR, Mckean-Cowdin R, Mueller BA. Neonatal vitamin D and childhood brain tumor risk. Int J Cancer. 2015 May 15; 136(10):2481–5. https://doi.org/10.1002/ijc.29291 PMID: 25348494

13. Pedersen CB, Bybjerg-Grauholm J, Pedersen MG, Grove J, Agerbo E, Bækvat-Hansen M, et al. The iPSYCH2012 case-cohort sample: new directions for unravelling genetic and environmental architectures of severe mental disorders. Mol Psychiatry. 2018 01; 23(1):6–14. https://doi.org/10.1038/mp.2017.196 PMID: 28924187

14. Horsdal HT, Agerbo E, McGrath JJ, Vilhjálmsdóttir BJ, Antonsen S, Closter AM, et al. Association of Childhood Exposure to Nitrogen Dioxide and Polygenic Risk Score for Schizophrenia With the Risk of Developing Schizophrenia. JAMA Netw Open. 2019 Nov 1; 2(11):e1914401. https://doi.org/10.1001/jamanetworkopen.2019.14401 PMID: 31675084
15. Mitchell C, Jennings C, Brambilla D, Aldrovandi G, Amedee AM, Beck I, et al. Diminished human immunodeficiency virus type 1 DNA yield from dried blood spots after storage in a humid incubator at 37 degrees C compared to -20 degrees C. J Clin Microbiol. 2008 Sep; 46(9):2945–9. https://doi.org/10.1128/JCM.00359-08 PMID: 18614660

16. Hollegaard MV, Thorsen P, Nørgaard-Pedersen B, Hougaard DM. Genotyping whole-genome-amplified DNA from 3- to 25-year-old neonatal dried blood spot samples with reference to fresh genomic DNA. Electrophoresis. 2009 Jul; 30(14):2532–5. https://doi.org/10.1002/elps.200800655 PMID: 19639574

17. Olney RS, Moore CA, Ojodu JA, Lindegren ML, Hannon WH. Storage and use of residual dried blood spots from state newborn screening programs. J Pediatr. 2006 May; 148(5):618–22. https://doi.org/10.1016/j.jpeds.2005.12.053 PMID: 16737872

18. Brown AL, de Smith AJ, Gant VU, Yang W, Scheurer ME, Walsh KM, et al. Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome. Blood. 2019 10 10; 134(15):1227–37. https://doi.org/10.1182/blood.2018890764 PMID: 31350265

19. Infinium Genotyping Data Analysis: A guide for analyzing Infinium genotyping data using the GenomeStudio Genotyping Module [Internet]. illumina.com. 2014 [cited 20 August 2019]. Available from: https://www.illumina.com/Documents/products/technote/technote_infinium_genotyping_data_analysis.pdf

20. Turner S, Armstrong LL, Bradford Y, Carlson CS, Crawford DC, Crenshaw AT, et al. Quality control procedures for genome-wide association studies. Curr Protoc Hum Genet. 2011 Jan;Chapter 1:Unit1.19.

21. Laurie CC, Doheny KF, Mirel DB, Pugh EW, Bierut LJ, Bhangale T, et al. Quality control and quality assurance in genotypic data for genome-wide association studies. Genet Epidemiol. 2010 Sep; 34 (6):591–602. https://doi.org/10.1002/gepi.20516 PMID: 20718045

22. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015; 4:7. https://doi.org/10.1186/s13742-015-0047-8 PMID: 25722852

23. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007 Sep; 81(3):559–75. https://doi.org/10.1086/501775 PMID: 17701901

24. Wiemels JL, Walsh KM, de Smith AJ, Metayer C, Gonseth S, Hanssen HM, et al. GWAS in childhood acute lymphoblastic leukemia reveals novel genetic associations at chromosomes 17q12 and 8q24.21. Nat Commun. 2018 01 18; 9:1.286. https://doi.org/10.1038/s41467-017-02596-9 PMID: 29348612

25. Hollegaard MV, Grove J, Thorsen P, Nørgaard-Pedersen B, Hougaard DM. High-throughput genotyping on archived dried blood spot samples. Genet Test Mol Biomarkers. 2009 Apr; 13(2):173–9. https://doi.org/10.1089/gtmb.2008.0073 PMID: 19371215

26. Mei JV, Li L, Rasmussen SA, Collier S, Frias JL, Honein MA, et al. Effect of specimen storage conditions on newborn dried blood spots used to assess Toxoplasma gondii immunoglobulin M (IgM). Clin Chim Acta. 2011 Feb; 412(5–6):455–9. https://doi.org/10.1016/j.cca.2010.11.028 PMID: 21114968

27. Koulman A, Prentice P, Wong MCY, Matthews L, Bond NJ, Eiden M, et al. The development and validation of a fast and robust dried blood spot based lipid profiling method to study infant metabolism. Metabolomics. 2014; 10(5):1018–25. https://doi.org/10.1007/s11306-014-0628-z PMID: 25177234

28. Hollegaard MV, Grove J, Grauholm J, Kreiner-Møller E, Bennelykke K, Nørgaard M, et al. Robustness of genome-wide scanning using archived dried blood spot samples as a DNA source. BMC Genet. 2011 Jul 4; 12:58. https://doi.org/10.1186/1471-2156-12-58 PMID: 21726430

29. Schwartz A, Baidjoe A, Rosenthal PJ, Dorsey G, Bousema T, Greenhouse B. The Effect of Storage and Extraction Methods on Amplification of Plasmodium falciparum DNA from Dried Blood Spots. Am J Trop Med Hyg. 2015 May; 92(5):922–5. https://doi.org/10.4269/ajtmh.14-0602 PMID: 25758652

30. Hannelius U, Lindgren CM, Melén E, Mainberg A, von Dobeln U, Kere J. Phenylketonuria screening registry as a resource for population genetic studies. J Med Genet. 2005 Oct; 42(10):e60. https://doi.org/10.1136/jmg.2005.032967 PMID: 16199543

31. Hollegaard MV, Grauholm J, Berglum A, Nyegaard M, Nørgaard-Pedersen B, Ørntoft T, et al. Genome-wide scans using archived neonatal dried blood spot samples. BMC Genomics. 2009 Jul 4; 10:297. https://doi.org/10.1186/1471-2164-10-297 PMID: 19575812

32. Wong N, Morley R, Saffery R, Craig J. Archived Guthrie blood spots as a novel source for quantitative DNA methylation analysis. BioTechniques. 2008 Oct; 45(4):423–4, 426, 428 passim. https://doi.org/10.2144/000112945 PMID: 18855769

33. Staunstrup NH, Starmawski A, Nyegaard M, Christiansen L, Nielsen AL, Berglum A, et al. Genome-wide DNA methylation profiling with MeDIP-seq using archived dried blood spots. Clin Epigenetics. 2016; 8:81. https://doi.org/10.1186/s13146-016-0242-1 PMID: 27462375
34. Beger RD, Dunn W, Schmidt MA, Gross SS, Kirwan JA, Cascante M, et al. Metabolomics enables precision medicine: "A White Paper, Community Perspective". Metabolomics. 2016; 12(10):149. https://doi.org/10.1007/s11306-016-1094-6 PMID: 27642271